Mouse GM-CSF protein | PRP100489

Mouse GM-CSF protein | PRP100489 | Gentaur UK, US & Europe Distribution

Product Category: Cytology

Application: Cytokines

Product Type: Cytokines

Sequence: Amino acid sequence derived from mouse CSF2 (NP_034099.2) (Met1-Lys141) was expressed.

Activity: Measured in a cell proliferation assay using FDC-P1 cells. The ED50 for this effect is typically 0.012-0.047 ng/mL. The ED50 for this effect is typically 0.012-0.047 ng/mL.

protein Lenght: The recombinant mouse CSF2 consists of 124 amino acids and predicts a molecular mass of 14.1 KDa. It migrates as an approximately 20.7 KDa band in SDS-PAGE under reducing conditions.

Preparation: HEK293 Cells

Purity: > 95 % as determined by SDS-PAGE

Formulation: Lyophilized from sterile PBS, pH 7.4.

Kit Component: N/A

Features & Benefits : N/A

Molecular Weight: 14.1 kDa

Usage Note: Always centrifuge tubes before opening. It is recommended to reconstitute the lyophilized Mouse GM-CSF protein in sterile ddH2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.

Storage Conditions: Lyophilized Mouse GM-CSF proteinshould be stored desiccated below -20°C. Upon reconstitution, the protein should be stored at 4°C between 2-7 days and for future use below -20°C. For long term storage it is recommended to add a carrier protein (0.90% HSA or BSA) . Please prevent freeze-thaw cycles.

Shipping: The product is shipped at ambient temperature.

Background: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.

Alternative Names: Csfgm; Gm-CSf; GMCSF; MGI-IGM; Granulocyte-macrophage colony-stimulating factor; CSF2

Search Names: Csfgm; Gm-CSf; GMCSF; MGI-IGM; Granulocyte-macrophage colony-stimulating factor; CSF2

Tag: GM-CSF